Microbiota-Driven Strategies for Managing IBD-Associated Risks: From Infections to Mental Health.

Patrycja Krynicka, Pablo Cortegoso Valdivia, Maciej Morawski, Wojciech Marlicz, Karolina Skonieczna-Żydecka, Anastasios Koulaouzidis

Abstract readReview

PubMed Full text at PMC Publisher

In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Microbiota-derived metabolites and cardiovascular implications in Inflammatory Bowel Disease (IBD).Molecular medicine (Cambridge, Mass.) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Patrycja KrynickaDepartment of Gastroenterology and Nutrition Disorders, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Bydgoszcz, Poland.ORCID 0000-0002-4694-7334

Pablo Cortegoso ValdiviaGastroenterology and Endoscopy Unit, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-8793-5890

Maciej MorawskiClinical Department of Ophthalmology, 10th Military Clinical Hospital with Polyclinic, 85-681 Bydgoszcz, Poland.

Wojciech MarliczDepartment of Gastroenterology, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0000-0002-2649-5967

Karolina Skonieczna-ŻydeckaDepartment of Human Nutrition and Metabolomics, Pomeranian Medical University, 71-460 Szczecin, Poland.ORCID 0000-0002-3430-9079

Anastasios KoulaouzidisDepartment of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark.ORCID 0000-0002-2248-489X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD) are increasingly acknowledged not merely as confined gastrointestinal disorders but as systemic immunometabolic syndromes. Central to this paradigm is the gut microbiota including non-bacterial components such as the virome, whose functional disruption marked by reduced short-chain fatty acids (SCFAs), increasingly implicated in pathogenic processes extending beyond intestinal mucosa. This review outlines how these alternations compromise the epithelial barrier and immune regulation, increasing the risk of recurrent

Indexed as

extraintestinal manifestations (EIMs)fecal microbiota transplantation (FMT)gut microbiotainflammatory bowel disease (IBD)live biotherapeutic products (LBPs)psychobiotics

Identifiers

PMID41599716

DOI10.3390/ph19010118

PMCPMC12845199

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.